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Background: Accumulating evidence indicates that partial inhibition of β-site APP-cleaving enzyme 1 (BACE1),
which initiates amyloid-β (Aβ) production, mitigates Alzheimer’s disease (AD)-like pathologies and memory deficits
in a battery of transgenic mouse models. However, our previous investigations suggest that therapeutic BACE1
suppression may be beneficial only if targeted on earlier stages of AD and encounter dramatic reductions in efficacy
during disease progression. This study was designed to test the possibility that a combination approach, aimed at
inhibiting BACE1 and boosting neprilysin (a major Aβ-degrading enzyme) activities, may be able to mechanistically
overcome the limited efficacy of anti-Aβ therapy in advanced AD.
Results: After crossbreeding between BACE1 heterozygous knockout (BACE1+/−), neprilysin transgenic (NEP) and
5XFAD mice, we analyzed the resultant mice at 12 months of age when 5XFAD controls showed robust amyloid-β (Aβ)
accumulation and elevation of BACE1 expression (~2 folds). Although haploinsufficiency lowered BACE1 expression
by ~50% in concordance with reduction in gene copy number, profound β-amyloidosis, memory deficits and
cholinergic neuron death were no longer rescued in BACE1+/− · 5XFAD mice concomitant with their persistently
upregulated BACE1 (i.e., equivalent to wild-type control levels). Notably, neprilysin overexpression not only prevented
Aβ accumulation but also suppressed the translation initiation factor eIF2α-associated elevation of BACE1 and
lowered levels of the β-secretase-cleaved C-terminal fragment of APP (C99) in NEP · 5XFAD mice. Interestingly,
these markers for β-amyloidogenesis in BACE1+/− · NEP · 5XFAD mice were further reduced to the levels reflecting
a combination of single BACE1 allele ablation and the abolishment of translational BACE1 upregulation. However,
since neprilysin overexpression was striking (~8-fold relative to wild-type controls), memory impairments, cholinergic
neuronal loss and β-amyloidosis were similarly prevented in NEP · 5XFAD and BACE1+/− · NEP · 5XFAD mice.
Conclusions: Our findings indicate that robust overexpression of neprilysin is sufficient to ameliorate AD-like phenotypes
in aged 5XFAD mice. We also found that Aβ-degrading effects of overexpressed neprilysin can block deleterious
BACE1-elevating mechanisms that accelerate Aβ production, warranting further study to test whether interventions
moderately activating neprilysin may be useful for boosting the limited efficacy of therapeutic BACE1 inhibition in
treating AD with established Aβ pathology.
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Figure 1 Western blot analysis of transgenic overexpression of
neprilysin in 5XFAD mice. Equivalent levels of neprilysin are
overexpressed in NEP · 5XFAD and BACE1+/− · NEP · 5XFAD mouse
brains (~8-fold relative to 5XFAD controls).
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The β-secretase, called β-site amyloid precursor protein-
cleaving enzyme 1 (BACE1), was identified as an aspartyl
protease that initiates the production of amyloid-β (Aβ)
peptides [1]. Given pathogenic roles of Aβ in AD [2,3],
BACE1 is one of the prime therapeutic targets to prevent
or treat this devastating neurodegenerative disorder [4-7].
It has been demonstrated that homozygous BACE1 knock-
out (BACE1−/−) prevents the development of AD-like path-
ologies and memory deficits in different transgenic lines of
amyloid precursor protein (APP)-overexpressing mice
[8-11]. Furthermore, BACE1 haploinsufficiency (BACE1+/−;
i.e., a therapeutic relevant model for 50% suppression)
[12-18] as well as chronic treatments with bioavailable
small-molecule BACE1 inhibitors (e.g., GRL-8234 and
TAK-070) [19-21] has been reported to partially reduce
cerebral Aβ concentrations and mitigate amyloid plaque
and tau pathologies, cholinergic neuron loss, mitochondrial
dysfunction, hippocampal synaptic failure, and memory
deficits in APP mice. However, some of these studies raise
concern that the beneficial outcomes associated with par-
tial BACE1 inhibition may decline during the progression
of AD [11,12,15,16,18,21].
It has been demonstrated that Aβ accumulation induces
BACE1 elevation in neurons surrounding the amyloid core
of plaques, which in turn further accelerates Aβ production
and plaque growth in brains of the 5XFAD mouse model
and AD patients [22-26]. Meanwhile, previous studies with
neprilysin transgenic and knockout mice have clearly
shown that neprilysin-dependent degradation of Aβ is crit-
ical for suppressing plaque development [27-30]. Notably,
we found that partial suppression of BACE1 with haploin-
sufficiency or the β-secretase inhibitor GRL-8234 was no
longer able to exert beneficial effects including memory im-
provements in advanced stages of 5XFADmice (≥12 months
of age) suffering from robust Aβ deposition, since it
failed to reverse BACE1 elevation and neprilysin reduction
in the brain [15,18,21]. Therefore, our results suggest that
monotherapeutic approaches targeting BACE1 may not be
sufficient to block a detrimental feed-forward link between
neprilysin reduction, increased levels of Aβ plaque forma-
tion and BACE1 elevation during the course of AD pro-
gression. In this study, we tested whether a combination
strategy that boosts Aβ degradation (neprilysin overexpres-
sion) and arrests Aβ production (BACE1 haploinsufficiency)
may be useful for mechanistically increasing the limited
therapeutic efficacies in 12-month-old 5XFAD mice.
Results
Effects of BACE1 haploinsufficiency combined with
neprilysin overexpression on β-amyloidogenic processing
of APP in aged 5XFAD mice
We used 5XFAD APP/presenilin-1 (PS1) transgenic mice
that represent a rapid-onset and aggressive amyloidmodel based on a combination of five familial AD (FAD)
mutations and the consequent acceleration of neurotoxic
Aβ42 production [9,10,31]. 5XFAD mice begin to develop
visible Aβ deposition as early as 2 months of age and ex-
hibit memory declines on a battery of hippocampus-
dependent tasks around 6 months concomitant with syn-
aptic dysfunction at the Schaffer collateral-CA1 pathway
[9,13,31-38]. We tested the effects of heterozygous BACE1
deletion (BACE1+/−), neprilysin overexpression (NEP) and
their combination (BACE1+/− · NEP) in 5XFAD mice at
12 months of age, which show extensive Aβ plaque path-
ology concomitant with significant BACE1 elevation and
neprilysin reduction and are no longer responsive to rescue
by BACE1 haploinsufficiency [15,16,18]. We first compared
the degree of neprilysin overexpression by quantitative im-
munoblot analysis of brain samples (Figure 1). As previ-
ously reported in hAPP-J20 transgenic mice engineered to
overexpress neprilysin [29,30], we confirmed robust over-
expression of neprilysin (859 ± 20%) in NEP · 5XFAD mice
relative to 5XFAD controls. Moreover, we found that the
addition of BACE1+/− gene ablation to these mice (i.e.,
BACE1+/− · NEP · 5XFAD) did not affect overexpression
levels of neprilysin (864 ± 31%).
Next, we investigated changes in the β-amyloidogenic
processing of APP (Figure 2). BACE1 expression levels
in 12-month-old 5XFAD mice were significantly in-
creased up to ~2 folds as compared with those in wild-
type control mice (p < 0.05) (Figure 2A, B). Consistent
with our previous results [15,18], although haploin-
sufficiency reduced BACE1 expression by ~50% in
5XFAD mice (p < 0.05), the residual levels of BACE1
in BACE1+/− · 5XFAD mouse brains were equivalent to
wild-type control levels (i.e., twice the gene copy number).
Interestingly, neprilysin overexpression in 5XFAD
mice also reversed the upregulation of BACE1 to
wild-type levels (p < 0.05). Of note, BACE1 levels
were indistinguishable between neprilysin transgenic
and wild-type control mice (data not shown), excluding
the possibility that neprilysin overexpression by itself
may directly affect BACE1 expression. A significant
Figure 2 Effects of a combination of BACE1 haploinsufficiency and neprilysin overexpression on β-amyloidogenic processing of APP in
12-month-old 5XFAD mice. (A) Representative immunoblots of protein extracts from hemibrain homogenates of mice. (B–E) Immunoreactive
bands were quantified and expressed as the percentage of 5XFAD control mice (n = 3–4 mice per group). Note that BACE1 expression is reduced
below wild-type controls in BACE1+/− · NEP · 5XFAD mice, as expected by a single BACE1 allele ablation and the complete abolishment of eIF2α
phosphorylation-dependent translational upregulation. Consequently, the β-secretase-cleaved C-terminal fragment of APP (C99) is also dramatically
reduced in these mice. * p < 0.05 vs. wild-type, # p < 0.05 vs. 5XFAD, § p < 0.05 vs. BACE1+/− · NEP · 5XFAD. All data are presented as mean ± SEM.
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served in BACE1+/− · NEP · 5XFAD mice as compared to
BACE1+/− · 5XFAD (p < 0.05) or NEP · 5XFAD (p = 0.06)
mice, indicating that a combination of BACE1 haploin-
sufficiency and neprilysin overexpression in 5XFAD mice
can further reduce BACE1 expression below wild-type
control levels (p < 0.05). Meanwhile, overexpressionlevels of full-length APP were not affected except for
the NEP · 5XFAD group, which showed a slight but
significant decrease compared with 5XFAD controls
(p < 0.05) (Figure 2A, C). The β-secretase-cleaved C-
terminal fragment of APP (β-CTF or C99) in 5XFAD
mice at 12 months of age was not affected by BACE1
haploinsufficiency, whereas C99 levels in NEP · 5XFAD
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controls (p < 0.05) (Figure 2A, D). Moreover, in ac-
cordance with the robust reduction of BACE1 expression,
C99 levels were also further reduced in BACE1+/− · NEP ·
5XFAD mice as compared with BACE1+/− · 5XFAD and
NEP · 5XFAD mice (p < 0.05).
Recent findings from our laboratory and others have
demonstrated that translational mechanisms through
overactivation of the eukaryotic initiation factor-2α
(eIF2α) phosphorylation pathway [15,18,24,39-43] rather
than transcriptional mechanisms [22,44,45] account for
BACE1 elevation found in advanced stages of 5XFAD
mice as well as sporadic AD cases. Therefore, we com-
pared levels of phosphorylated eIF2α (Figure 2A, E) in
association with the alterations of BACE1 expression. In
agreement with our previous studies [15,18], haploinsuf-
ficiency lowered BACE1 expression by ~50% in concord-
ance with the reduction of gene copy number but failed
to affect phospho-eIF2α-dependent BACE1-elevating
mechanisms in 12-month-old 5XFAD mice; therefore,
BACE1 expression in BACE1+/− · 5XFAD mice remained
upregulated or equivalent to wild-type levels. Import-
antly, neprilysin overexpression significantly suppressed
eIF2α phosphorylation without affecting total eIF2α
levels in 5XFAD mice (p < 0.05), leading to the reversal
of translational BACE1 upregulation. Moreover, a com-
bination of BACE1 haploinsufficiency and neprilysin
overexpression in 5XFAD mice almost completely
blocked eIF2α phosphorylation, which in turn was able
to lower BACE1 expression below wild-type controls in
BACE1+/− · NEP · 5XFAD mice as a consequence of the
ablation of a single BACE1 allele and the blockade of
translational upregulation.
Effects of BACE1 haploinsufficiency combined with neprilysin
overexpression on β-amyloidosis in aged 5XFAD mice
We further examined how Aβ plaque loads were af-
fected by BACE1 and/or neprilysin manipulations in
5XFAD mice (Figure 3A). In accordance with our
previous findings [15,18], we confirmed that BACE1
haploinsufficiency alone was not sufficient to reduce
extensive Aβ deposition found in the hippocampus
(Figure 3B) or cerebral cortex (Figure 3C) of 5XFAD
mice at 12 months of age (n = 2). In contrast, as re-
ported in the hAPP-J20 mouse model [29,30], trans-
genic overexpression of neprilysin almost completely
prevented Aβ plaque formation in 5XFAD mice (p < 0.05).
A combination of BACE1 haploinsufficiency and neprilysin
overexpression also similarly blocked plaque develop-
ment (p < 0.05), indicating no further reduction in
brain Aβ burden in BACE1+/− · NEP · 5XFAD mice as
compared with NEP · 5XFAD mice. Consistent with
Aβ immunostaining, sandwich ELISAs also showed that
total Aβ42 levels in 5 M guanidine-extracted brains weresignificantly and equivalently reduced in NEP · 5XFAD
and BACE1+/− · NEP · 5XFAD mice (p < 0.05), but not in
BACE1+/− · 5XFAD mice, as compared with 5XFAD con-
trols (Figure 3D). Interestingly, ELISAs specific to oligo-
meric forms of Aβ revealed that all of BACE1+/− deletion,
neprilysin overexpression and their combination induced
similar levels of reductions in soluble Aβ oligomers in
5XFAD mice (p < 0.05) (Figure 3E).
Effects of BACE1 haploinsufficiency combined with
neprilysin overexpression on memory deficits and
cholinergic neuron loss in aged 5XFAD mice
Finally, we examined whether genetic manipulations of
BACE1 and/or neprilysin can rescue memory deficits in
5XFAD mice, using the hippocampus-dependent con-
textual fear conditioning paradigm (Figure 4A). Wild-
type control mice exhibited a robust conditioned fear
response as assessed by freezing (the absence of all but
respiratory movements) when placed back into the con-
ditioning chamber 24 h after training. 5XFAD mice at
12 months of age showed significantly reduced levels of
freezing compared with wild-type controls (p < 0.05),
whereas contextual memory remained impaired in
BACE1+/− · 5XFAD mice as reported previously [18]. In
contrast, contextual memory deficits in 5XFAD mice
were rescued almost completely back to wild-type levels
in NEP · 5XFAD and BACE1+/− · NEP · 5XFAD mice
(p < 0.05). Meanwhile, freezing levels were indistin-
guishable between wild-type, BACE1+/−, NEP and
BACE1+/− · NEP mice (Figure 4B), demonstrating that
BACE1+/− reduction, neprilysin overexpression and their
combination does not affect baseline memory perfor-
mances on the non-5XFAD transgenic background.
The septohippocampal cholinergic pathway plays an
important role in memory performances including the
contextual fear conditioning [46], while cholinergic
neuron loss is found in several AD transgenic mouse
models such as 5XFAD and APP23 [15,42,47]. Therefore,
we further examined whether BACE1 and/or neprilysin
manipulations can rescue neurodegeneration by analyzing
cholinergic neurons in the medial septum and the vertical
limb of the diagonal band (Ch1/2) that provide the cholin-
ergic innervation to the hippocampus (Figure 4C).
Immunostaining for choline acetyltransferase (ChAT: a
cholinergic marker) revealed that the number of choliner-
gic neurons was significantly reduced in 12-month-old
5XFAD mice as compared with that of wild-type controls
(p < 0.05) (Figure 4D). Consistent with behavioral improve-
ments, ChAT-positive neuron number in NEP · 5XFAD as
well as BACE1+/− · NEP · 5XFAD mice was significantly
higher than that of 5XFAD mice (p < 0.05) and equivalent
to wild-type control levels. In contrast, the number of cho-
linergic neurons in BACE1+/− · 5XFAD mice was as low as
that of 5XFAD controls (n = 2), as reported in our previous
Figure 3 Effects of a combination of BACE1 haploinsufficiency and neprilysin overexpression on β-amyloidosis in 12-month-old 5XFAD
mice. (A) Brain sections were immunostained with the 6E10 anti-Aβ antibody. Shown are representative photomicrographs of the hippocampal
and cortical regions. Scale bar = 500 μm. (B, C) Percentage area occupied by Aβ deposits in the hippocampus (B) and cerebral cortex (C) was
measured for quantification (n = 2–5 mice per group). (D, E) Levels of total Aβ42 in guanidine extracts (D) and soluble Aβ oligomers (E) were
quantified by sandwich ELISAs and expressed in nanograms and picograms per milligram of total protein, respectively (n = 4–6 mice per group).
Significant and equivalent reductions in all Aβ measurements are observed in NEP · 5XFAD and BACE1+/− · NEP · 5XFAD mice. # p < 0.05 vs. 5XFAD.
All data are presented as mean ± SEM.
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overexpression alone or in combination with BACE1 hap-
loinsufficiency can prevent both contextual memory defi-
cits and cholinergic neuron death in advanced stages of
5XFAD mice.Discussion
It is widely accepted that both accelerated Aβ production
and compromised Aβ clearance underlie the molecular
pathogenesis of AD [48,49]. In particular, the Aβ-generating
enzyme BACE1 is increased [15,18,22,42,44,45,50,51] while
Figure 4 Effects of a combination of BACE1 haploinsufficiency and neprilysin overexpression on memory deficits and cholinergic
neuron loss in 12-month-old 5XFAD mice. (A, B) Mice were trained with a CS-US pairing for contextual fear conditioning (n = 6–11 mice per
group). 5XFAD mice showed significantly lower levels of contextual freezing than wild-type mice when tested 24 h after training. NEP · 5XFAD
and BACE1+/− · NEP · 5XFAD mice are rescued almost completely back to wild-type control levels of contextual memory. (C) Brain sections were
immunostained for the cholinergic marker ChAT. Shown are representative photomicrographs of ChAT-immunoreactive neurons in the medial
septum of mice. Scale bar = 200 μm. (D) The number of ChAT-positive neurons in the medial septum and the vertical limb of the diagonal band
(Ch1/2), which provide the cholinergic innervation to the hippocampus, was counted for quantification (n = 2–5 mice per group). Cholinergic
neuronal death associated with 5XFAD is prevented in NEP · 5XFAD and BACE1+/− · NEP · 5XFAD mice. * p < 0.05 vs. wild-type, # p < 0.05 vs. 5XFAD.
All data are presented as mean ± SEM.
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[18,42,52] during disease progression in 5XFAD mouse
as well as human AD brains. Our previous studies
using aged 5XFAD mice have shown that a monothera-
peutic β-secretase-suppressing strategy is not sufficient
to surmount robust Aβ accumulation, cholinergic neu-
rodegeneration or cognitive deficits in advanced AD
because of its failure to attenuate deleterious BACE1-
elevating and neprilysin-reducing mechanisms [15,18,21].
In this study, we tested whether a combination of boosting
neprilysin and inhibiting BACE1 activities may provide a
useful approach to synergistically improve β-amyloidosis
and memory deficits in 5XFAD mice already suffering
from extensive plaque pathology. Consistent with previous
results [15,16,18], BACE1 haploinsufficiency was no lon-
ger able to exert any beneficial effects in 5XFAD mice at
12 months of age. In contrast, transgenic overexpression
of neprilysin in combination with BACE1 haploinsuffi-
ciency showed almost complete rescues of memory
deficits of 5XFAD mice as assessed by the hippocampus-
dependent contextual fear conditioning and their choliner-
gic neuron death in the medial septum. However, we also
found that transgenic overexpression of neprilysin alone
sufficed to exert similar beneficial or neuroprotective
effects in aged 5XFAD mice. This can be accounted for by
the findings that neprilysin overexpression was so robust
(~8-fold higher than nontransgenic controls) that it almost
completely prevented plaque development in the hippo-
campus and cerebral cortex of 5XFAD mice concomitant
with significant reductions of total Aβ42 irrespective of
the presence of BACE1+/− gene deletion. Our observation
is in agreement with previous work that showed greatly
reduced plaque burden in hAPP-J20 mice crossbred with
the same neprilysin transgenic line [29,30]. Collectively, it
seems likely that strong Aβ-removing effects of overex-
pressed neprilysin in 5XFAD mice do not allow us to dem-
onstrate the advantage of combining BACE1 reduction
and neprilysin upregulation (if any) in further facilitating
the beneficial outcomes.
Given that soluble Aβ oligomers may represent toxic
mediators of synaptic and mnemonic failure in AD
[53-55], we further compared changes in oligomeric
forms of Aβ. Levels of Aβ oligomers were also signifi-
cantly and equivalently reduced in NEP · 5XFAD and
BACE1+/− · NEP · 5XFAD mice, both of which showed
memory improvements. Interestingly, we found that al-
though BACE1+/− · 5XFAD mice failed to exhibit signifi-
cant mitigation of total Aβ accumulation or plaque
pathology, similar levels of oligomer reductions occurred
in brains of these mice, probably reflecting a conse-
quence of lower BACE1-dependent Aβ production.
Nevertheless, memory function remained deteriorated in
BACE1+/− · 5XFAD mice, suggesting that it is important
to reduce both soluble Aβ oligomers and depositedinsoluble Aβ species for the success of therapeutic inter-
ventions. This view is supported by accumulating evi-
dence that indicates that Aβ plaques induce structural
and functional disruption of neuron networks [56-60].
It should also be noted that there is some discrepancy
concerning the relationship between neprilysin overex-
pression and improvements of hippocampus-dependent
memory deficits in AD mouse models in spite of the
consistent abolishment of plaque formation. Meilandt
et al. [30] reported that transgenic overexpression of
neprilysin under the αCaMKII promoter did not reduce
pathogenic Aβ oligomers such as trimers and dodeca-
mers (Aβ*56) in hAPP-J20 mice and thus failed to rescue
spatial learning and memory deficits in the Morris water
maze. In contrast, we showed that neprilysin overexpres-
sion in the same transgenic line significantly lowered Aβ
oligomers and ameliorated contextual fear memory im-
pairments in 5XFAD mice. Likewise, neprilysin overex-
pression under the PrP promoter in hAPP-J20 mice [61]
or through the lentiviral vector-mediated gene transfer
in APPswe/PS1dE9 mice [62] has been found to rescue
spatial memory declines in the water maze, although Aβ
oligomer levels were not measured in these studies.
Conceivably, the controversial results may arise form
different approaches used to overexpress neprilysin (e.g.,
the onset, amounts, neuronal populations of overexpres-
sion, etc.), AD mouse models applied and behavioral
tasks. However, it is most likely that reductions of sol-
uble Aβ oligomers in our NEP · 5XFAD model, despite
the potential inability of neprilysin to directly degrade
such Aβ assemblies [29], may be attributable to reduced
de novo Aβ generation (via blocking BACE1-elevating
mechanisms, as discussed below in more detail), leading
to memory improvements in conjunction with the pre-
vention of plaque deposition.
Although the degrees of Aβ reductions, mnemonic
amelioration and neuronal protection were indistin-
guishable between NEP · 5XFAD and BACE1+/− · NEP ·
5XFAD mice, we found the advantage of combining
BACE1 haploinsufficiency and neprilysin overexpression
in more robustly suppressing the β-amyloidogenic pro-
cessing of APP. Translational elevations of BACE1 ex-
pression (~2 folds relative to wild-type control levels)
occurred in 12-month-old 5XFAD mice through overac-
tivation of the eIF2α phosphorylation pathway, as re-
ported previously [15,18,22,24,40,42]. Haploinsufficiency
lowered BACE1 expression by ~50% in concordance
with the reduction of gene copy number, while eIF2α
phosphorylation was not affected and consequently
BACE1 remained upregulated (i.e., equivalent to wild-
type levels in spite of the ablation of a single BACE1
allele) in BACE1+/− · 5XFAD mice. Interestingly, we
found that translational elevation of BACE1 was com-
pletely blocked concomitant with a significant reduction
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servation is consistent with our recent evidence directly
demonstrating that genetic inhibition of the PERK-
mediated eIF2α phosphorylation pathway can reverse
BACE1 upregulation in 5XFAD mice [42,43]. It has been
proposed that Aβ accumulation induces BACE1 eleva-
tion in neurons in the close vicinity of plaques, which in
turn further accelerates Aβ generation and plaque
growth in 5XFAD mouse as well as human AD brains
[22-26]. Therefore, it is conceivable that Aβ-degrading
effects of overexpressed neprilysin prevent Aβ accumu-
lation in 5XFAD brains, thereby suppressing the eIF2α
phosphorylation-dependent upregulation of BACE1 ex-
pression associated with plaques. More importantly, we
demonstrate that neprilysin overexpression in combin-
ation with BACE1 haploinsufficiency in 5XFAD mice
almost completely abolishes eIF2α phosphorylation,
resulting in BACE1 expression below wild-type controls
in BACE1+/− · NEP · 5XFAD mice as expected by a single
BACE1 allele ablation under the reversal of translational
upregulation.
Conclusions
The present study shows that transgenic overexpression
of neprilysin is sufficient to reduce Aβ accumulation and
almost completely prevent cholinergic neuron loss and
memory deficits in aged 5XFAD mice. Accordingly,
there is no significant difference in AD-like phenotypes
between NEP · 5XFAD and BACE1+/− · NEP · 5XFAD
mice. In the experimental setting with robust neprilysin
overexpression (~8-fold), it seems difficult to unequivo-
cally demonstrate the advantage of combining partial
BACE1 inhibition and neprilysin upregulation in further
facilitating their beneficial outcomes during advanced
stages of AD. However, the results presented here pro-
vide clear evidence that boosting neprilysin-dependent
degradation of Aβ can block BACE1-elevating signaling
mechanisms associated with progressive plaque for-
mation in 5XFAD mice. Consequently, BACE1 ex-
pression and the direct β-metabolite of APP (C99) in
BACE1+/− · NEP · 5XFAD mice are further reduced to
the levels reflecting a combination of single BACE1
allele ablation (BACE1+/−) and the abolishment of trans-
lational BACE1 upregulation (NEP). These findings sug-
gest that activation of neprilysin function may be useful
for complementing the limited efficacy of direct BACE1
suppression in reducing β-amyloidogenic processing of
APP in advanced AD. This is quite important given that
over-inhibition of β-secretase activities is suggested to in-
duce potentially mechanism-based adverse effects on the
basis of an increased number of novel BACE1 substrates
that have been discovered beside APP [4,5,63,64]. Our
gene-based findings warrant further mechanistic investi-
gations of synergistic benefits that may be brought aboutby combined treatments with β-secretase inhibitors (e.g.,
GRL-8234 and TAK-070) [19-21] and feasible therapeutic
agents capable of moderately increasing neprilysin
expression or activities (e.g., γ-hydroxybutyrate) [65] in




We used 5XFAD mice (Tg6799 line) that co-overexpress
FAD mutant forms of human APP (Swedish mutation:
K670N, M671L; Florida mutation: I716V; London
mutation: V717I) and PS1 (M146L and L286V muta-
tions) transgenes under transcriptional control of the
neuron-specific Thy-1 promoter [9,10,31]. Hemizygous
5XFAD transgenic mice (C57Bl/6 background) were
bred to heterozygous BACE1 knockout (BACE1+/−) mice
(C57Bl/6 background) (Stock number: 004714, The
Jackson Laboratory, Bar Harbor, ME, USA) [11,66] to
obtain bigenic mice with the BACE1+/− · 5XFAD+/−
genotype. BACE1+/− · 5XFAD+/− mice were further
crossbred to hemizygous neprilysin transgenic mice
(C57Bl/6 background) (Stock number: 005086, The
Jackson Laboratory) that overexpress human neprilysin
under control of the αCaMKII promoter [29,30], yielding
animals with the genotypes of interest. Genotyping was
performed by PCR analysis of tail DNA. All experiments
were done blind with respect to the genotype of mice at
12 months of age when 5XFAD control mice showed ex-
tensive Aβ plaque pathology that was accompanied by
significant BACE1 elevation and neprilysin reduction and
no longer responsive to mitigation by partial BACE1
suppression [15,16,18,21]. Procedures were conducted in
accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and ap-
proved by the Nathan Kline Institute Animal Care and
Use Committee.
Contextual fear conditioning
Contextual fear conditioning was tested as described
previously [14,32,67]. In this behavioral assay, mice learn
to associate a distinct context (CS: conditioned stimulus)
with aversive footshock (US: unconditioned stimulus)
through hippocampus-dependent mechanisms [68,69].
During training, mice were placed in the conditioning
chamber for 3 min and then received a footshock
(0.8 mA, 2 s). After the shock delivery, mice were left in
the chamber for another 30 s. Contextual fear memory
was evaluated by scoring freezing behavior (the absence
of all movement except for that needed for breathing)
for 3 min when the mice were placed back into the same
conditioning chamber 24 h after training. The auto-
mated FreezeFrame system (Coulbourn Instruments,
Allentown, PA, USA) was used to score the amount of
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ficed for immunoblotting and ELISA experiments, and
others were perfused for immunohistochemistry.
Immunoblot analysis
Hemibrain samples were taken from the mice under
deep isoflurane anesthesia and were snap-frozen for
biochemical assays. For western blot analysis, each sam-
ple was homogenized in 8-fold volumes of cold
homogenization medium containing 70 mM sucrose,
210 mM mannitol, 2 mM HEPES, 0.1 mM EDTA and
protease/phosphatase inhibitor cocktail and centrifuged
at 10,000 g for 10 min to remove any insoluble material.
Protein concentrations were determined by a BCA pro-
tein assay kit (Pierce, Rockford, IL, USA), and 10–50 μg
of protein was run on NuPAGE 4–12% or 10% Bis-Tris
gels (Invitrogen, Carlsbad, CA, USA) and transferred to
nitrocellulose membrane. After blocking, membranes
were probed with the following primary antibodies:
anti-neprilysin (1:1,000, ab951, Abcam, Cambridge, MA,
USA), anti-BACE1 (1:1,000, B0681, Sigma-Aldrich, St.
Louis, MO, USA), an antibody that recognizes C-
terminal epitope in APP (1:1,000, C1/6.1, kindly pro-
vided by Dr. Paul Mathews, Nathan Kline Institute)
to detect full-length APP/C-terminal fragments, anti-
phospho-eIF2α (Ser51) (1:1,000, #3398, Cell Signaling
Technology, Danvers, MA, USA), anti-eIF2α (1:2,000,
#9722, Cell Signaling Technology), and anti-β-actin
(1:15,000, AC-15, Sigma-Aldrich). They were then incu-
bated with horseradish peroxidase-conjugated secondary
IgG. Immunoblot signals were visualized by an ECL
chemiluminescence substrate reagent kit (Pierce) and
quantified by densitometric scanning and image analysis
using Quantity One software (Bio-Rad Laboratories,
Hercules, CA, USA). Duplicates of each sample in immu-
noblot assays were averaged for comparison between
groups.
ELISAs of soluble Aβ oligomers and total Aβ42
To measure the concentrations of soluble Aβ oligomers,
each hemibrain sample was homogenized in 8-fold vol-
umes of homogenization medium, as described above.
To quantitate total levels of Aβ42, the other hemibrain
was extracted in 8-fold volumes of cold 5 M guanidine
HCl plus 50 mM Tris HCl (pH 8.0) buffer and centri-
fuged at 20,000 g for 1 h at 4°C to remove insoluble
material. Final guanidine HCl concentrations were
below 0.1 M. Protein concentrations were determined
by a BCA protein assay kit (Pierce). Supernatant frac-
tions were analyzed by well-established human Aβ ELISA
kits specific to oligomeric forms of Aβ (27725, IBL
America, Minneapolis, MN, USA) and Aβ42 (KHB3441,
Invitrogen) according to the protocols of the manufac-
turers. Optical densities at 450 nm of each well were readon a VersaMax tunable microplate reader (Molecular
Devices, Sunnyvale, CA, USA), and sample Aβ oligomer
and Aβ42 concentrations were determined by compari-
son with the respective standard curves. Aβ oligomer and
Aβ42 concentration values were normalized to total brain
protein concentrations and expressed in picograms and
nanograms per milligram of total protein, respectively.
Aβ immunohistochemistry
Mice were transcardially perfused with 0.1 M phosphate
buffered saline (PBS, pH7.4), followed by 4% paraformal-
dehyde in PBS under deep isoflurane anesthesia. Brains
were postfixed for 24 h in 4% paraformaldehyde in PBS
at 4°C and transferred to PBS. The brain was sectioned
coronally at 30 μm using a vibratome (VT1200, Leica
Microsystems, Wetzlar, Germany), and successive sec-
tions were stored in PBS containing 0.05% sodium
azide at 4°C. Three sections per mouse taken at levels
between −1.7 and −1.9 mm to bregma according to the
mouse brain atlas of Franklin and Paxinos [70] were
stained by the avidin-biotin peroxidase complex (ABC)
method as described previously [13,14,71]. Briefly, the
sections were incubated overnight at 4°C with mouse
monoclonal anti-Aβ1–16 (6E10) antibody (1:200, SIG-
39347; Covance, Princeton, NJ, USA). The ABC kit
(PK-2200; Vector Laboratories, Burlingame, CA, USA)
was utilized with 3,3’-diaminobenzidine tetrahydrochlo-
ride (DAB) as a chromogen to visualize the reaction
product. The sections were then mounted on charged
slides, dehydrated in a series of alcohol, cleared in xy-
lene and covered with a coverslip. Light microscopy
was conducted on an Axioskop 2 microscope equipped
with an AxioCaM HRc digital camera (Zeiss, Oberkochen,
Germany) for capturing images. Semi-quantitative analysis
was performed using AxioVision imaging software with
the AutoMeasure module (Zeiss). The threshold optical
density that discriminated staining from background was
determined and held constant for all quantifications. Iden-
tified objects were individually inspected by the same in-
vestigator to confirm the object as a plaque or not in a
blinded manner. Percentage area occupied by Aβ deposits
in the hippocampus and cortex was assessed bilaterally to
compare plaque burdens between groups.
ChAT immunohistochemistry
Three brain sections per mouse were stained by the
ABC method for immunohistochemical analysis of
ChAT-positive neurons in the Ch1/2 comprising the
medial septum and the vertical limb of the diagonal
band, as described [15]. The sections were taken at levels
between +1.2 and +0.8 mm to bregma according to the
atlas of Franklin and Paxinos [70] and incubated over-
night at 4°C with polyclonal goat anti-ChAT antibody
(1:200; AB144P, Millipore, Billerica, MA, USA). The
Devi and Ohno Molecular Brain  (2015) 8:19 Page 10 of 11DAB staining was performed using the ABC kit (PK-
6105, Vector Laboratories). After identified objects,
following thresholding under an Axioskop 2 micro-
scope (Zeiss), were individually inspected in a blinded
manner to confirm the object as a neuron or not, the
number of ChAT-positive neurons in the Ch1/2 was
counted using AxioVision imaging software (Zeiss). The
average of ChAT-positive neuron number per section
from each mouse was used to calculate group medians.Statistical analysis
Significant differences between the groups were deter-
mined by a one-way ANOVA and post-hoc Fisher’s PLSD
tests were applied following all ANOVAs showing sig-
nificance. Data were presented as mean ± SEM and the
level of significance was set for p value less than 0.05.
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